Takeda is investing approximately $764.6 million to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan.

The investment aligns with Takeda’s capital allocation policy of “Investing in Growth Drivers”, through disciplined and focused investments in value-creating business opportunities, enabling Takeda to establish a world-class end-to-end manufacturing facility for PDTs at its Juso, Osaka plant.

According to the company, the new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. The new site increases the capacity of Takeda’s current plasma manufacturing site in Narita, Japan almost five-fold and will enable Takeda to serve more patients in Japan sustainably, as well as add incremental capacity to its global manufacturing network.

The facility will be built to the highest global manufacturing standards, including the latest automation and advanced digital technologies. It will be a fully integrated plant, comprising of teardown, fractionation, purification, filling, finishing capabilities as well as a cold storage warehouse.

In addition, the design will be environmentally friendly to support Takeda’s goal of achieving net-zero greenhouse gas emissions related to operations including scopes 1 and 2 before 2035. Takeda’s existing Narita plasma manufacturing site will continue day-to-day operations until at least the end of the decade, with continued necessary investments for maintenance.

“Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years,” said Milano Furuta, president of the Japan Pharma Business Unit at Takeda. “This new investment will strengthen our ability to continuously and reliably bring high-quality PDTs to a growing number of patients in Japan and worldwide. We will engage in discussions with the Ministry of Health, Labour and Welfare to ensure we are contributing to sustainable patient care in an area of high unmet need in Japan.”

“We are pleased to make this investment in Japan, demonstrating our commitment to our fast-growing PDT business and to our home country,” said Thomas Wozniewski, global manufacturing & supply officer at Takeda. “Japan will play an even more critical role in our global manufacturing network, contributing to supply chain resilience globally. The new facility will provide a plasma fractionation capacity of more than 2 million liters per year. The company will unleash the power of automation and digitalization to deliver high quality products to patients reliant on PDTs, including those with diseases for which there are no alternative treatments.”